Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema (left eye)
ICD-10 E09.3592 is a billable code used to indicate a diagnosis of drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema (left eye).
E09.3592 refers to diabetes mellitus that is induced by drugs or chemicals, specifically characterized by the presence of proliferative diabetic retinopathy in the left eye without associated macular edema. This condition arises when certain medications or toxic substances lead to insulin resistance or impaired insulin secretion, resulting in elevated blood glucose levels. Proliferative diabetic retinopathy is a severe complication of diabetes, marked by the growth of new blood vessels in the retina, which can lead to vision loss. The absence of macular edema indicates that while there is significant retinal damage, the central vision area remains unaffected. Management of this condition often involves careful monitoring of blood glucose levels, with an emphasis on maintaining HbA1c levels below 7% to minimize complications. Insulin therapy may be required to achieve glycemic control, especially in cases where oral hypoglycemics are ineffective due to the drug-induced nature of the diabetes. Regular ophthalmologic evaluations are crucial to monitor retinal changes and prevent further vision impairment.
Detailed medication history, HbA1c levels, and treatment plans.
Management of patients with drug-induced diabetes and monitoring for complications.
Ensure clear documentation of the drug responsible for diabetes and its management.
Retinal examination findings, imaging results, and treatment plans.
Evaluation and treatment of diabetic retinopathy.
Document specific findings related to proliferative changes and absence of macular edema.
Used for routine follow-up of diabetic retinopathy.
Document visual acuity, retinal findings, and treatment plan.
Ophthalmologists should ensure detailed documentation of retinal changes.
Specifying the eye involved is crucial for treatment planning and monitoring, as it affects the management of diabetic retinopathy and potential vision outcomes.
